Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy

BACKGROUND: Multiple sclerosis (MS) patients with breakthrough disease on immunomodulatory drugs are frequently offered to switch to natalizumab or immunosuppressants. The effect of natalizumab monotherapy in patients with breakthrough disease is unknown. METHODS: This is an open-label retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo-Trivino, Tamara, Mowry, Ellen M., Gajofatto, Alberto, Chabas, Dorothee, Crabtree-Hartman, Elizabeth, Cree, Bruce A., Goodin, Douglas S., Green, Ari J., Okuda, Darin T., Pelletier, Daniel, Zamvil, Scott S., Vittinghoff, Eric, Waubant, Emmanuelle
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033401/
https://www.ncbi.nlm.nih.gov/pubmed/21304907
http://dx.doi.org/10.1371/journal.pone.0016664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033401/
https://www.ncbi.nlm.nih.gov/pubmed/21304907
http://dx.doi.org/10.1371/journal.pone.0016664

Ejemplares similares